Last reviewed · How we verify
bevacizumab, erlotinib
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Used for Non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, breast cancer, renal cell carcinoma, Other cancers.
At a glance
| Generic name | bevacizumab, erlotinib |
|---|---|
| Also known as | bevacizumab (Avastin), erlotinib (Tarceva), Avastin, Tarceva |
| Sponsor | Swiss Cancer Institute |
| Drug class | VEGF inhibitor, EGFR inhibitor |
| Target | VEGF-A, EGFR |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab works by binding to VEGF-A, preventing it from interacting with its receptor and thus inhibiting the formation of new blood vessels that tumors need to grow. Erlotinib, on the other hand, binds to the ATP-binding pocket of EGFR, preventing the receptor from phosphorylating downstream targets and thereby inhibiting cell proliferation and survival signals.
Approved indications
- Non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, breast cancer, renal cell carcinoma
- Other cancers
Common side effects
- Hypertension
- Diarrhea
- Rash
- Fatigue
- Nausea
Key clinical trials
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations (PHASE3)
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (PHASE1)
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (PHASE2)
- Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer (PHASE1)
- KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
- A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bevacizumab, erlotinib CI brief — competitive landscape report
- bevacizumab, erlotinib updates RSS · CI watch RSS
- Swiss Cancer Institute portfolio CI